Overview Topiramate 25 mg Tablets Under Fasting Conditions Status: Completed Trial end date: 2001-06-01 Target enrollment: Participant gender: Summary The objective of this study was to compare the rate and extent of absorption of topiramate 25 mg tablets (test) versus Topamax® (reference) administered as 2 x 25 mg tablets under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: Topiramate